Home > Boards > US Listed > Biotechs > METACRINE (MTCR)

MET-409 phase-1b data in NASH don’t look so

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 752
Posts 116,068
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021 GlobeNewswire Inc. - 6/17/2021 8:05:00 AM
Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform Seeking Alpha - 6/14/2021 12:30:43 PM
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH GlobeNewswire Inc. - 6/2/2021 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 4:31:05 PM
Metacrine to Present at 2021 Jefferies Healthcare Conference GlobeNewswire Inc. - 5/26/2021 8:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:03:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:01:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:00:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:59:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:58:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:56:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:56:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:55:23 PM
Metracrine rises 10.27% after hours as CMO and CEO acquires shares Seeking Alpha - 5/21/2021 5:30:44 AM
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meet... GlobeNewswire Inc. - 5/19/2021 8:05:00 AM
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis GlobeNewswire Inc. - 5/18/2021 8:05:00 AM
Metacrine reports Q1 results Seeking Alpha - 5/13/2021 5:31:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 4:18:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2021 4:11:33 PM
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results GlobeNewswire Inc. - 5/13/2021 4:05:00 PM
Metacrine to Present at 2021 RBC Global Healthcare Conference GlobeNewswire Inc. - 5/11/2021 8:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 6:37:36 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/9/2021 4:11:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2021 4:11:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/5/2021 4:10:54 PM
DewDiligence Member Level  Sunday, 02/28/21 07:18:09 PM
Re: None
Post # of 11 
MET-409 phase-1b data in NASH don’t look so good:

#msg-162210410

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences